Unique ID issued by UMIN | UMIN000033970 |
---|---|
Receipt number | R000038734 |
Scientific Title | Effect of the experimental diet on lipid metabolism |
Date of disclosure of the study information | 2018/09/01 |
Last modified on | 2019/09/01 16:15:20 |
Effect of the experimental diet on lipid metabolism
Effect on lipid metabolism
Effect of the experimental diet on lipid metabolism
Effect on lipid metabolism
Japan |
Healthy subjects
Adult |
Others
NO
To prove clinical benefits associated with 12 week daily intake of active test food on blood lipid level.
Safety,Efficacy
Total blood cholesterol
Blood LDL cholesterol
Blood HDL cholesterol
Blood triglyceride
Body weight
BMI
Incidence of adverse and of side effects
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Treatment
Food |
Intake 6 capsules those contain test food three times a day (after each meal), for 12 weeks.
Intake 6 capsules those contain no test food three times a day (after each meal), for 12 weeks.
40 | years-old | <= |
60 | years-old | >= |
Male
1)Males aged 40 to 60 at resistration.
2) LDL-cholesterol >= 120mg/dL
3) Subjects giving written informed consent.
1) Subjects who constantly use medicines, supplements having a possibility of affecting test results.
2) Subjects who have previous and/or current medical history of serious disease having a possibility of affecting test results.
3) Subjects who excessive alcohol intake and excess smoker.
4) Subjects who have extremely irregular dining habits, and subjects who have midnight work or irregular shift work.
5) Subjects who have previous medical history of drug and/or food (especially gelatin) allergy.
6) Subjects who are participating the other clinical tests. Subjects who participated within 4-weeks prior to the current study and/or who plan to participate the other clinical tests.
7) Subjects who donated over 200mL blood and/or blood components within the last one month to the current study.
8) Males who donated over 400mL blood and/or blood components within the last three month to the current study.
9) Males who will be collected over 1200mL blood and/or blood components, when the sampling amounts within the last twelve month are adding to the planned sampling amounts of this study.
10) Subjects who are positive for infectious.
11) Others who have been determined ineligible by principal investigator or sub-investigator.
20
1st name | |
Middle name | |
Last name | Seiji Shioda |
SHIODA Life Science Inc.
President
Harks Roppongi Bildg. 6F, 6-15-21 Roppongi, Minato-ku, Tokyo, Japan
03-6804-5371
shioda@hoshi.ac.jp
1st name | |
Middle name | |
Last name | Makoto Ichinohe |
CPCC Company Limited
Planning and Sales Department
4F Chusin Building, 3-3-5 Uchikanda Chiyoda-ku, Tokyo 101-0047, JAPAN
03-5927-3112
cpcc-contact@cpcc.co.jp
CPCC Company Limited
SHIODA Life Science Inc.
Profit organization
NO
2018 | Year | 09 | Month | 01 | Day |
Unpublished
Completed
2018 | Year | 07 | Month | 20 | Day |
2018 | Year | 07 | Month | 20 | Day |
2018 | Year | 09 | Month | 04 | Day |
2019 | Year | 06 | Month | 30 | Day |
2019 | Year | 06 | Month | 30 | Day |
2018 | Year | 08 | Month | 31 | Day |
2019 | Year | 09 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038734